Aman Chauhan, MD, discusses sequencing decisions when treating patients with gastroenteropancreatic neuroendocrine tumors.
Aman Chauhan, MD, a medical oncologist at University of Kentucky, discusses sequencing decisions when treating patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Currently, sequencing for patients with GEP-NETs is largely dictated by the presentation or degree of tumor progression. Patients with metastatic disease, especially bone metastases who are symptomatic, would likely be treated with peptide receptor radionuclide therapy upfront, according to Chauhan.
In asymptomatic patients with slow-growing tumors or low-bulk metastatic disease, Chauhan recommends somatostatin analogs and potentially a mTOR inhibitor afterwards before the patient is exposed to radionuclide therapy. Chauhan continues to search for conclusive data to guide sequencing decisions for patients with GEP-NETs.